CoChat

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

Open access
Modest, Dominik Paul, Karthaus, Meinolf, Fruehauf, Stefan, Graeven, Ullrich, Müller, Lothar, König, Alexander Otto, Fischer von Weikersthal, Ludwig, Caca, Karel, Kretzschmar, Albrecht, Goekkurt, Eray, Haas, Siegfried, Kurreck, Annika, Stahler, Arndt, Held, Swantje, Jarosch, Armin, Horst, David, Reinacher-Schick, Anke, Kasper, Stefan, Heinemann, Volker, Stintzing, Sebastian, Trarbach, Tanja · 2022 · Journal of Clinical Oncology
Cited by 86

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

PURPOSE: The randomized PANAMA trial investigated the efficacy of panitumumab (Pmab) when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients with RAS wild-type metastatic colorectal cancer. METHODS: Following first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab, responding patients (stable disease or partial or complete remission) were randomly assigned (1:1, open-label) to maintenance treatment with either FU/FA plus Pmab or FU/FA alone. The primary objective was to demonstrate superiority of progression-free survival (PFS, time from random assignment until progression or death) in favor of FU/FA plus Pmab with a hazard ratio (HR) of 0.75, a power of 80%, and a significance level of 10%. Secondary end points included overall survival, objective response rate of maintenance therapy, and toxicity. Survival end points were analyzed by the Kaplan-Meier method and compared by log-rank test and Cox regressions. Dichotomous variables were compared by Fisher's exact test; odds ratios were indicated when appropriate. The trial is registered with ClinicalTrials.gov ( NCT01991873 ). RESULTS: Overall, 248 patients were randomly assigned and received maintenance therapy with either FU/FA plus Pmab (125 patients) or FU/FA alone (123 patients). At data cutoff, with 218 events (of 218 needed), PFS of maintenance therapy was significantly improved with FU/FA plus Pmab (8.8 months v 5.7 months; HR, 0.72; 80% CI, 0.60 to 0.85; P = .014). Overall survival (event rate 54%) numerically favored the FU/FA plus Pmab arm (28.7 months v 25.7 months; HR, 0.84; 95% CI, 0.60 to 1.18; P = .32). Objective response rates were 40.8% in patients receiving FU/FA plus Pmab versus 26.0% in patients receiving FU/FA alone (odds ratio, 1.96; 95% CI, 1.14 to 3.36; P = .02). The most frequent Common Terminology Criteria for Adverse Event grade ≥ 3 event during maintenance therapy was skin rash (7.2%). CONCLUSION: In RAS wild-type metastatic colorectal cancer, maintenance therapy with FU/FA plus Pmab induced a significantly superior PFS compared with FU/FA alone. If active maintenance therapy is aspired following induction therapy with FU/FA and oxaliplatin plus Pmab, FU/FA plus Pmab appears to be the most favorable option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.01332

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 21

  1. 10.1056/NEJMoa1403108 · DOI · Paper page
  2. 10.1200/JCO.19.01340 · DOI · Paper page
  3. 10.1093/annonc/mdx175 · DOI · Paper page
  4. 10.1016/j.clcc.2014.12.011 · DOI
  5. 10.1200/JCO.2013.53.2473 · DOI · Paper page
  6. 10.1200/JCO.2016.34.15_suppl.3504 · DOI · Paper page
  7. 10.1200/JCO.2009.27.4860 · DOI · Paper page
  8. 10.1200/JCO.2005.03.0106 · DOI · Paper page
  9. 10.1002/ijc.32110 · DOI
  10. 10.1016/S1470-2045(14)70106-8 · DOI
  11. 10.1016/j.ejca.2018.06.024 · DOI
  12. 10.1200/JCO.2021.39.3_suppl.15 · doi:10.1200/jco.2021.39.3_suppl.15
  13. 10.1001/jamaoncol.2019.1467 · DOI · Paper page
  14. 10.1016/S1470-2045(11)70102-4 · DOI · Paper page
  15. 10.1016/S0140-6736(14)62004-3 · DOI · Paper page
  16. 10.1093/annonc/mdv011 · DOI
  17. 10.1016/j.ejca.2019.07.006 · DOI
  18. Kurreck A, 2020, J Cancer Res Clin Oncol, 146, 2681, 10.1007/s00432-020-03257-z · DOI
  19. 10.1016/j.ejca.2015.06.116 · DOI · Paper page
  20. 10.1016/j.ctrv.2021.102226 · DOI
  21. 10.1001/jamaoncol.2019.4489 · DOI

Cited by

See all 86

Metadata

Authors
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Kurreck, A., Stahler, A., Held, S., Jarosch, A., Horst, D., Reinacher-Schick, A., Kasper, S., Heinemann, V., Stintzing, S., & Trarbach, T.
Venue
Journal of Clinical Oncology
Published
2022-01-01
Volume
40
Issue
1
Pages
72-82
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3201195457
Cited by
86
References
15
FWCI
4.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). https://app.cochat.ai/papers/10.1200/jco.21.01332
The paper
Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Kurreck, A., Stahler, A., Held, S., Jarosch, A., Horst, D., Reinacher-Schick, A., Kasper, S., Heinemann, V., . . . Trarbach, T. (2022). Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01332

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.